Journal
EMERGING INFECTIOUS DISEASES
Volume 18, Issue 7, Pages 1072-1080Publisher
CENTERS DISEASE CONTROL
DOI: 10.3201/eid1807.101371
Keywords
-
Categories
Funding
- Cubist Pharmaceuticals
- National Institutes of Health/National Institute of Allergy and Infectious Diseases [HHSN272200700055C: NRS 18, HHSN272200700055C: NRS 19, HHSN272200700055C: NRS 21, HHSN272200700055C: NRS 22, HHSN272200700055C: NRS 23, HHSN272200700055C: NRS 24, HHSN272200700055C: NRS 26, HHSN272200700055C: NRS 27]
Ask authors/readers for more resources
Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is often fatal. To determine predictors of risk for death, we conducted a retrospective cohort study. We examined 699 episodes of MRSA bacteremia involving 603 patients admitted to an academic medical center in New York City during 2002-2007. Data came from chart reviews, hospital databases, and recultured frozen MRSA specimens. Among the 699 episodes, 55 were caused by vancomycin intermediate resistant S. aureus strains, 55 by heteroresistant vancomycin-intermediate S. aureus strains, and 589 by non vancomycin-resistant strains; 190 (31.5%) patients died. We used regression risk analysis to quantify the association between clinical correlates and death. We found that older age, residence in a nursing home, severe bacteremia, and organ impairment were independently associated with increased risk for death; consultation with an infectious disease specialist was associated with lower risk for death; and MRSA strain types were not associated with risk for death.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available